文献速递脊柱关节炎类风湿关节炎

荷兰银屑病关节炎与中轴型脊柱关节炎患者达标减量TNF抑制剂的疗效:DRESS-PS试验24个月随访

Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial.
PubMed 文献 · Lancet Rheumatol · 2025-07-24

DRESS-PS试验的12个月观察性延伸研究,在荷兰Sint Maartenskliniek开展,纳入114例银屑病关节炎或中轴型脊柱关节炎患者。24个月时低疾病活动度比例干预组67%对对照组72%,校正差值5%(95%CI -15至24),未校正分析超过非劣效界值,插补后差值2%(95%CI -18至16)落在非劣效界值内。作者认为达标减量TNF抑制剂在维持低疾病活动度方面持续有效且安全达2年。

要点

  • 24个月低疾病活动度比例:原干预组67%(45/67) vs 原对照组72%(23/32),校正差值5%(95%CI -15至24;p=0.64)。
  • 插补缺失数据后校正差值2%(95%CI -18至16;p=0.85),落在原试验预设20%非劣效界值内。
  • 至少一次不良事件:原干预组78/79(99%) vs 原对照组31/35(89%),差值10%(95%CI -1至21;p=0.060)。

核心结论

  • 达标减量TNF抑制剂在银屑病关节炎和中轴型脊柱关节炎患者中维持低疾病活动度达2年,作者认为持续有效且安全。
  • 作者提出未来研究应探索在常规诊疗中实施减量策略所面临的挑战。

研究设计与样本

  • 本研究为原始12个月开放标签非劣效DRESS-PS试验的12个月观察性延伸研究,在荷兰Sint Maartenskliniek(Nijmegen和Woerden)开展。
  • 原始试验纳入年龄16岁及以上、银屑病关节炎或中轴型脊柱关节炎且低疾病活动度稳定至少6个月的患者,随机分配至达标减量策略组(干预组,延长TNF抑制剂给药间隔,使剂量为限定日剂量的100%、66%、50%或0%)或达标不减量策略组(对照组)。
  • 延伸研究允许所有患者进行达标减量,治疗决策由医患共同决策制定;共114例参与(原干预组79例,其中银屑病关节炎40例、中轴型脊柱关节炎39例;原对照组35例,其中银屑病关节炎18例、中轴型脊柱关节炎17例)。
  • 主要结局为24个月时低疾病活动度患者比例在原干预组与原对照组之间的差异,按随机分层因素校正,分别在有和无插补情况下与原始DRESS-PS试验预设的20%非劣效界值比较,非劣效性根据校正95%CI判定。
  • 平均年龄50.0岁(SD 14.5);70例(61%)为男性,44例(39%)为女性;DRESS-PS试验注册于荷兰试验注册库,NL6771。

主要发现

  • 24个月时低疾病活动度比例:原干预组67%(45/67) vs 原对照组72%(23/32),校正差值5%(95%CI -15至24;p=0.64),未校正分析超过预设非劣效界值。
  • 插补缺失数据后校正差值2%(95%CI -18至16;p=0.85),落在非劣效界值内。
  • 全24个月至少一次不良事件:原干预组78/79(99%) vs 原对照组31/35(89%),差值10%(95%CI -1至21;p=0.060)。
  • 特别关注的不良事件(感染和注射部位反应)两组间无显著差异。

关键数值与推荐

  • 非劣效界值为原始DRESS-PS试验预设的20%,非劣效性根据校正95%CI判定。
  • 24个月低疾病活动度校正差值5%(95%CI -15至24;p=0.64),未校正分析超过20%非劣效界值。
  • 插补缺失数据后校正差值2%(95%CI -18至16;p=0.85),落在20%非劣效界值内。
  • 至少一次不良事件差值10%(95%CI -1至21;p=0.060)。

临床怎么用

  • 原文结论认为达标减量TNF抑制剂在银屑病关节炎和中轴型脊柱关节炎患者中维持低疾病活动度达2年持续有效且安全。
  • 作者提出未来研究应探索在常规诊疗中实施减量策略所面临的挑战。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Results of the DRESS-PS trial showed that a tapering strategy with TNF inhibitors is non-inferior to continuation of the same TNF inhibitor dose for up to 12 months in patients with psoriatic arthritis and axial spondyloarthritis. This study aimed to describe the effectiveness of TNF inhibitor tapering for up to 24 months in patients who participated in the DRESS-PS trial. METHODS: This study was a 12-month observational extension of the original 12-month, open-label, non-inferiority DRESS-PS trial conducted at the Sint Maartenskliniek, Nijmegen and Woerden, the Netherlands. Patients aged 16 years and older with psoriatic arthritis or axial spondyloarthritis and stable low disease activity for at least 6 months participated in the original DRESS-PS trial. Patients were randomly assigned to either a treat-to-target tapering strategy (the intervention group), which involved extending the interval between TNF inhibitor doses, resulting in doses of 100%, 66%, 50%, or 0% of the defined daily dose, or to a treat-to-target strategy without tapering (the control group). All patients who participated in the DRESS-PS trial were eligible to participate in this extension study, in which treat-to-target tapering was allowed for all patients, and treatment decisions were made through shared decision making between physicians and patients. The primary outcome was the difference between the original intervention and control groups in the proportion of patients with low disease activity at 24 months; this difference (adjusted for stratification factors at randomisation) was compared, without and with imputation, with the prespecified non-inferiority margin of 20% from the original DRESS-PS trial, and non-inferiority was determined from the adjusted 95% CIs. There was no involvement of people with lived experience of psoriatic arthritis or axial spondyloarthritis in the design, recruitment, conduct, analysis, or reporting of this extension study. The DRESS-PS trial was registered with the Dutch Trial Register, NL6771. FINDINGS: Between Jan 8, 2020, and Oct 10, 2022, 114 of the 122 patients from the DRESS-PS trial participated in this extension study: 79 from the original intervention group (40 with psoriatic arthritis, 39 with axial spondyloarthritis) and 35 from the original control group (18 with psoriatic arthritis, 17 with axial spondyloarthritis). Mean age was 50·0 years (SD 14·5). 70 (61%) patients were men and 44 (39%) were women. The proportion of patients with low disease activity at 24 months was 67% (45 of 67 patients) in the intervention group and 72% (23 of 32 patients) in the control group, with an adjusted difference of 5% (95% CI -15 to 24; p=0·64), which exceeded the prespecified non-inferiority margin. With imputation of missing data, the adjusted difference was 2% (-18 to 16; p=0·85), which fell within the non-inferiority margin. 78 (99%) of 79 patients in the intervention group and 31 (89%) of 35 patients in the control group had at least one adverse event over the full 24-month study period (difference 10% [-1 to 21]; p=0·060). There were no significant differences between groups in adverse events of special interest: infections and injection site reactions. INTERPRETATION: Treat-to-target tapering of TNF inhibitors remains effective and safe for the maintenance of low disease activity for up to 2 years in patients with psoriatic arthritis and axial spondyloarthritis. Future research should explore the challenges to implementation of tapering strategies in routine care in these patients. FUNDING: ReumaNederland.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Peeters ACD, Michielsens CAJ, Mahler EAM, et al. Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial. Lancet Rheumatol. 2025. PMID: 40716447. doi:10.1016/S2665-9913(25)00070-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。